Navigation Links
Acorda Therapeutics to Host Analyst and Investor Reception

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr 25, 2007 - Acorda Therapeutics, Inc.(R) (Nasdaq: ACOR) today announced that Dr. Lauren Krupp, Professor of Neurology at Stony Brook University, will present data from Acorda's Phase 3 clinical trial of Fampridine-SR in multiple sclerosis at their analyst and investor reception on May 2, 2007. This reception will follow a presentation of this data at the American Academy of Neurology (AAN) annual meeting.

Dr. Krupp's presentation will begin at 7:00 pm Eastern Time (ET) and will be able via a live webcast at http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c= 194451&eventID=1529938

Archived versions of the webcast will be available for 90 days on our website at http://phx.corporate-ir.net/phoenix.zhtml?c= 194451&p=irol-irhome. (Due to their length, these URLs may need to be copied/pasted into your Internet browser's address field. Remove extra spaces if they exist.)

The platform presentation of the Phase 3 clinical trial of Fampridine-SR data at the AAN meeting will take place on May 2, 2007 at 4:15 pm ET. This abstract was selected to be part of the Scientific Highlights program, which spotlights the top five percent of the more than 1600 abstracts accepted for presentation at this meeting. This presentation was also selected for a second highlights session, Multiple Sclerosis Scientific Topic Highlights, to be presented on May 3, 2007 at 7:00 pm ET. The AAN meeting will take place at the Hynes Convention Center in Boston, MA.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause act
'"/>




Page: 1 2

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics Presents Data from its Phase 3 Study of Fampridine-SR in Multiple Sclerosis at the American Academy of Neurology Meeting
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acorda Therapeutics Host Analyst and Investor Reception
(Date:1/15/2014)... -- Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... CGM System as a non-invasive, wireless continuous glucose ... Doman , Executive Chairman and Interim CEO of ... Capital Markets, Tenth Annual Equity Conference. ... to prospective corporate partners and investors at 9:00 ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ... rapid growth of these markets. The ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ... Summary,Although the past decade has seen the ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... May 24, 2011 Reportlinker.com announces that ... in its catalogue: Pharmaceuticals ... Report (Global) http://www.reportlinker.com/p0503954/Pharmaceuticals-Industry-Report---Top-500-Pharmaceuticals-Industry-Report-Global.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... Report Plimsoll Publishing Ltd. ...
... Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ... Patou, M.D., chief medical officer, is scheduled to present at ... on Wednesday, May 25, 2011 at noon BST. Dr. Patou ... A live audio webcast of Pacira,s presentation can ...
Cached Medicine Technology:Reportlinker Adds Pharmaceuticals Industry Report - Top 500 Pharmaceuticals Industry Report (Global) 2Reportlinker Adds Pharmaceuticals Industry Report - Top 500 Pharmaceuticals Industry Report (Global) 3Reportlinker Adds Pharmaceuticals Industry Report - Top 500 Pharmaceuticals Industry Report (Global) 4Pacira Pharmaceuticals, Inc. to Present at UBS Global Specialty Pharmaceuticals Conference 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... 10 Once-daily Keppra XR(TM) (levetiracetam) extended-release tablets ... mg--enabling doctors to simplify patients, treatment plans by ... day. (Photo: http://www.newscom.com/cgi-bin/prnh/20090410/NY97244 )According to ... and Neurology , patients are more likely ...
... embracing new ways of communicating the latest aesthetic enhancement options by turning ... ... (Vocus) April 10, 2009 -- The founder and director of the Arizona ... exploring new and innovative ways of reaching out to patients in the ...
... The Sutter Health network of doctors, hospitals and ... for 2008. Sutter Health,s combined 2008 systemwide income from ... other services was $463 million, compared to $471 million ... $277 million in investment income and changes in net ...
... one of 14 given recent warning, will remain on the ... Bowing to the pleas of hospice experts, the U.S. Food ... from the market an unapproved liquid morphine painkiller given to ... the FDA,s Center for Drug Evaluation and Research, told the ...
... MISSION VIEJO, Calif., April 9 The Ensign Group, ... its Mt. Ogden Health & Rehabilitation Center in Ogden, ... and Medicaid Services, Special Focus Facility program.(Logo: ... small part of what we,re accomplishing as we strive ...
... NEW YORK (April 9, 2009) -- A newly discovered gene ... according to a study by researchers at Weill Cornell Medical ... Cancer Research , may lead to more accurate tests ... different type of fusion than researchers have found in cancer ...
Cached Medicine News:Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 2Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 3Health News:New Keppra XR(TM) Dosage Strength Offers Simplified Treatment Option for People Living With Partial-Onset Seizures 4Health News:Scottsdale, Arizona Cosmetic Plastic Surgeon Reaches Out to Patients with State-of-the-Art New Website 2Health News:Scottsdale, Arizona Cosmetic Plastic Surgeon Reaches Out to Patients with State-of-the-Art New Website 3Health News:Sutter Health Announces 2008 Financial Performance 2Health News:Sutter Health Announces 2008 Financial Performance 3Health News:FDA Reverses Stance on Removal of Morphine Painkiller 2Health News:The Ensign Group Successfully Graduates Third Nursing Home From CMS Special Focus Program 2Health News:Gene fusion discovery may lead to improved prostate cancer test 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: